)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Racura Oncology
Racura Oncology (RAC) investor relations material
Racura Oncology Q1 2027 TU earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q1 2027 TU earnings summary21 Oct, 2026
Executive summary
Clinical programs advanced: HARNESS-1 and CPACS cleared their first dose cohorts without dose-limiting toxicities; cash was $30.7m at quarter end.
Management expects the cash balance to fund committed activities into mid-CY2028.
Financial highlights
Cash and cash equivalents were $30.735m at 30 September 2026, down from $34.290m at the prior quarter end.
Net operating cash outflow was $3.542m; interest received was $496k and government grants and tax incentives were $115k.
FY2025 R&D Tax Incentive refunds totalled $2.905m, including a further $117,875 refund for eligible overseas R&D.
Outlook and guidance
Cash was estimated to provide 8.68 quarters of funding; management expects funding for committed activities into mid-CY2028.
After quarter end, HARNESS-1 was cleared to escalate RC220 to 100 mg/m²; CPACS progressed to its next dose level.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Racura Oncology
- Net loss more than doubled as R&D accelerated, but strong funding supports clinical progress.RAC
H2 2026 - RC220, a MYC-targeting drug, leads a fully funded late-stage pipeline with major milestones ahead.RACInvestor presentation
- RC220 clinical milestones achieved and $34.3M cash position secures funding into CY2028.RACQ4 2026 TU
- RC220 offers a novel, cardioprotective cancer therapy targeting a $7B global market.RACInvestor Presentation
- RC220 delivers novel MYC-targeted cancer therapy with strong IP, clinical promise, and market potential.RACInvestor presentation
- RC220 advances in oncology trials with strong IP, major market targets, and secured funding.RACAGM 2025 presentation
- Strong cash position and clinical progress underpin robust outlook through 2027.RACQ3 2026 TU
- RC220 clinical milestones, narrowed net loss, and strengthened leadership drive future growth.RACH2 2025
- Major clinical, financial, and leadership milestones achieved, with strong shareholder support.RACAGM 2024
Racura Oncology
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Race Oncology Limited is an Australian-based pharmaceutical company focused on the development and commercialization of oncology therapies. The company is dedicated to researching and advancing treatments for cancer, particularly through its drug discovery and development programs. Race Oncology employs precision medicine approaches and targets specific cancer-related pathways to address unmet needs in cancer care. The company is headquartered in Sydney, Australia, and its shares are listed on the ASX.